Comparison of morphine and ketorolac for intravenous patient-controlled analgesia in postoperative cancer patients.
OBJECTIVE
To compare the effectiveness of intravenous patient-controlled (i.v.-PCA) ketorolac to i.v.-PCA morphine in the treatment of postoperative pain in cancer patients.


METHODS
In a double-blind, prospective, randomized trial, patients received either morphine in 1 mg/ml concentration or ketorolac 5 mg/ml for postoperative pain control. On arrival to the postanesthesia care unit (PACU), the patients received 2 ml of medication every 5 min, until satisfactory analgesia was achieved. If pain persisted after 20 ml of study drug had been administered, 0.1 mg/kg morphine was given i.m. On discharge from the PACU, the patients were placed on an i.v.-PCA pump. All patients received a basal infusion of 1 ml/h with a 1-ml on-demand bolus and a lockout interval of 10 min. Patients were offered 0.1 mg/kg morphine IM every 6 h, which they could refuse.


METHODS
University Cancer Center.


METHODS
Seventy patients scheduled for abdominal or truncal cancer operations.


METHODS
Visual analog pain scores (VAPS) and Visual analog sedation scores (VASS) were used to measure the quality of pain control achieved either with ketorolac or morphine. The incidence of side effects was documented.


RESULTS
The VAPS were comparable between the groups. Patients in the ketorolac group requested more supplemental i.m. morphine. However, the total morphine dose and incidence of side effects was significantly higher in patients receiving i.v.-PCA morphine.


CONCLUSIONS
These results indicate that ketorolac supplemented with small doses of morphine is associated with a lower incidence of nausea, vomiting, and pruritus compared to morphine alone. This combination should be considered where immunosuppression from operation and administration of morphine is undesirable.
Bosek
V
V
Department of Anesthesiology, University of South Florida College of Medicine, Tampa.
Miguel
R
R
D000368:Aged; D016058:Analgesia, Patient-Controlled / Q000009:adverse effects; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D020910:Ketorolac; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage* / Q000009:adverse effects; D009369:Neoplasms / Q000601:surgery*; D010149:Postoperative Pain / Q000209:etiology / Q000628:therapy*; D011446:Prospective Studies; D014046:Tolmetin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D018712:Analgesics, Non-Narcotic; D009020:Morphine; D014046:Tolmetin; D020910:Ketorolac